All In Biotech

Drug Trial Radar · NCT02859727

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

An Open-label, Non-randomized Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

37

Actual

Start

Sep 8, 2016

Primary completion

Jan 30, 2025

Study completion Jan 30, 2025

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
First posted
Aug 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were treated previously with PI3Kδ inhibitors other than CDZ173. The study is open-label designed to establish the long-term safety, tolerability, efficay and pharmacokinetics of CDZ173 in the target population.

Conditions

  • Activated PI3Kdelta Syndrome (APDS); PASLI Disease

Interventions

  • CDZ173Drug

    140 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Number of Participants With (S)AEs During Treatment With CDZ173Time frame: 6 years 3 months

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • Pharming Investigative Site

    Bethesda, Maryland

  • Pharming Investigative Site

    Minsk, Belarus

  • Pharming Investigative Site

    Prague, CZE, Czechia

  • Pharming Investigative Site

    Dresden, Germany

  • Pharming Investigative Site

    Brescia, BS, Italy

  • Pharming Investigative Site

    Palermo, PA, Italy

  • Pharming Investigative Site

    Rotterdam, Netherlands

  • Pharming Investigative Site

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.